XTL Biopharmaceuticals Ltd. XTLB
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | |||
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | -43.02% | -33.45% | -46.09% | ||
| Total Receivables | -- | -- | -- | ||
| Inventory | -- | -- | -- | ||
| Prepaid Expenses | 75.86% | 8.47% | -59.15% | ||
| Finance Division Loans and Leases Current | -- | -- | -- | ||
| Total Finance Division Other Current Assets | -- | -- | -- | ||
| Other Current Assets | 327.27% | -- | -21.43% | ||
| Total Current Assets | -34.51% | -19.31% | -46.24% | ||
|
|
|||||
| Total Current Assets | -34.51% | -19.31% | -46.24% | ||
| Net Property, Plant & Equipment | -- | -- | -- | ||
| Long-term Investments | -- | -- | -- | ||
| Goodwill | -- | -- | -- | ||
| Total Other Intangibles | 904.21% | 0.00% | 0.00% | ||
| Finance Div Loans & Leases LT | -- | -- | -- | ||
| Total Finance Div Other LT Assets | -- | -- | -- | ||
| Total Other Assets | -- | -- | -- | ||
| Total Assets | 252.43% | -16.77% | -42.04% | ||
|
|
|||||
| Total Accounts Payable | 22,600.00% | 1.23% | -50.00% | ||
| Total Accrued Expenses | 165.85% | -- | 10.81% | ||
| Short-term Debt | -- | -- | -- | ||
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | ||
| Finance Division Debt Current | -- | -- | -- | ||
| Total Finance Division Other Current Liabilities | -- | -- | -- | ||
| Total Other Current Liabilities | -- | -- | -- | ||
| Total Current Liabilities | 971.36% | 1.23% | 10.16% | ||
|
|
|||||
| Total Current Liabilities | 971.36% | 1.23% | 10.16% | ||
| Long-Term Debt | -- | -- | -- | ||
| Short-term Debt | -- | -- | -- | ||
| Capital Leases | -- | -- | -- | ||
| Finance Division Debt Non Current | -- | -- | -- | ||
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | ||
| Total Other Liabilities | -- | -- | -- | ||
| Total Liabilities | 1,412.14% | 1.23% | 10.16% | ||
|
|
|||||
| Common Stock & APIC | 2.48% | 0.00% | 0.00% | ||
| Retained Earnings | -0.48% | -0.31% | -1.14% | ||
| Treasury Stock & Other | 0.00% | 0.00% | 0.00% | ||
| Total Common Equity | 144.82% | -17.84% | -44.49% | ||
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | ||
| Preferred Stock Non Redeemable | -- | -- | -- | ||
| Preferred Stock Convertible | -- | -- | -- | ||
| Preferred Stock, Others | -- | -- | -- | ||
| Total Preferred Equity | -- | -- | -- | ||
|
|
|||||
| Total Common Equity | 144.82% | -17.84% | -44.49% | ||
| Total Preferred Equity | -- | -- | -- | ||
| Total Minority Interest | -- | -- | -- | ||
| Total Equity | 144.82% | -17.84% | -44.49% | ||
|
|
|||||